Fig. 4

The combinations of the 4-lncRNA signature risk with clinical features. (A) Multivariate cox analysis of the 4-lncRNA signature risk score and clinical features with 2-year DFS in the entire group (N = 223). 4-lncRNA signature risk score, AFP and TNM stages are independent risk indicators for 2-year DFS (P < 0.05); (B) ROC analyses of model 1-4 with 2-year DFS. Model 1 (the combination of the 4-lncRNA signature risk score with AFP and TNM stages) had the largest AUC (72.02%) in all combined models; (C) Nomogram consisted of 4-lncRNA signature risk score, AFP and TNM stages for 1-year and 2-year DFS; (D) Calibration curves for integrated 4-lncRNA signature with AFP and TNM stages for 1-year DFS and 2-year DFS. RS: the 4-lncRNA signature risk score